Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526025 | 0.76 | HTT (0.46) | HTTBAZ2BTSHRKDM4EMAPT | |
| SCHEMBL21126678 | 0.76 | HTT (0.46) | HTTBAZ2BTSHRKDM4EMAPT | |
| SCHEMBL23091412 | 0.75 | HTT (0.48) | HTTBAZ2BTSHRKDM4EMAPT | |
| SCHEMBL31404132 | 0.74 | HTT (0.47) | HTTBAZ2BTSHRKDM4EMAPT | |
| SCHEMBL23529448 | 0.73 | HTT (0.46) | HTTBAZ2BTSHRKDM4EMAPT | |
| SCHEMBL18381001 | 0.72 | CHEK1 (0.32) | CHEK1CHEK2 | |
| SCHEMBL2493878 | 0.72 | BAZ2B (0.46) | HTTBAZ2BTSHRKDM4EMAPT | |
| SCHEMBL25402123 | 0.72 | HTT (0.46) | HTTBAZ2BTSHRKDM4EMAPT | |
| SCHEMBL2367517 | 0.71 | TSHR (0.47) | HTTBAZ2BTSHRKDM4EMAPT | |
| SCHEMBL20954695 | 0.68 | HTT (0.47) | HTTBAZ2BTSHRKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125637-A1 | ELECTROACTIVE BIOCOMPATIBLE HYDROGEL STRUCTURES | UNIV NORTHWESTERN (US) | 2026-05-07 | — | — | US | disclosed |
| US-12534702-B2 | Electroactive biocompatible hydrogel structures | NORTHWESTERN UNIVERSITY (US) | 2026-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125637-A1 | ELECTROACTIVE BIOCOMPATIBLE HYDROGEL STRUCTURES | CD44, ILK, EPCAM | HTT 1379/4885BAZ2B 2930/4885TSHR 1037/4885 |
| US-12534702-B2 | Electroactive biocompatible hydrogel structures | ILK, CD44, GJB2 | HTT 676/4885BAZ2B 2643/4885TSHR 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.